IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,905,679 | +15.8% | 549,067 | +4.8% | 0.18% | +14.2% |
Q2 2023 | $21,502,469 | +46.8% | 524,067 | +17.7% | 0.16% | +52.0% |
Q1 2023 | $14,645,258 | -16.7% | 445,197 | -4.4% | 0.10% | -14.3% |
Q4 2022 | $17,588,665 | -11.9% | 465,700 | +3.2% | 0.12% | -15.6% |
Q3 2022 | $19,964,000 | -5.5% | 451,351 | -20.9% | 0.14% | -19.0% |
Q2 2022 | $21,126,000 | +14.2% | 570,692 | +14.2% | 0.17% | +38.1% |
Q1 2022 | $18,502,000 | -35.1% | 499,547 | -46.7% | 0.13% | -30.8% |
Q4 2021 | $28,502,000 | +17.0% | 936,635 | +28.9% | 0.18% | +9.6% |
Q3 2021 | $24,361,000 | +10.5% | 726,359 | +31.5% | 0.17% | +9.9% |
Q2 2021 | $22,042,000 | +64.3% | 552,566 | +123.8% | 0.15% | +34.8% |
Q1 2021 | $13,412,000 | -3.9% | 246,954 | 0.0% | 0.11% | +1.8% |
Q4 2020 | $13,963,000 | +16.0% | 246,954 | -2.7% | 0.11% | -2.7% |
Q3 2020 | $12,038,000 | -19.5% | 253,700 | 0.0% | 0.11% | -28.5% |
Q2 2020 | $14,959,000 | -3.2% | 253,700 | -3.1% | 0.16% | -7.6% |
Q1 2020 | $15,454,000 | -2.2% | 261,700 | 0.0% | 0.17% | +1.2% |
Q4 2019 | $15,809,000 | -10.0% | 261,700 | -10.7% | 0.17% | -27.5% |
Q3 2019 | $17,566,000 | -6.4% | 293,200 | 0.0% | 0.23% | -0.4% |
Q2 2019 | $18,761,000 | -41.2% | 293,200 | -25.4% | 0.23% | -42.6% |
Q1 2019 | $31,917,000 | +136.9% | 393,200 | +57.8% | 0.41% | +97.1% |
Q4 2018 | $13,471,000 | +30.5% | 249,200 | +24.5% | 0.21% | +51.1% |
Q3 2018 | $10,326,000 | +59.1% | 200,200 | +28.5% | 0.14% | +33.0% |
Q2 2018 | $6,492,000 | +3.7% | 155,800 | +9.7% | 0.10% | -3.7% |
Q1 2018 | $6,260,000 | -12.4% | 142,000 | 0.0% | 0.11% | -13.7% |
Q4 2017 | $7,143,000 | -1.5% | 142,000 | -0.7% | 0.12% | -2.4% |
Q3 2017 | $7,250,000 | +29.6% | 143,000 | +30.0% | 0.13% | +21.0% |
Q2 2017 | $5,596,000 | -27.1% | 110,000 | -42.4% | 0.10% | -29.5% |
Q1 2017 | $7,679,000 | +8.5% | 191,000 | +29.1% | 0.15% | -8.0% |
Q4 2016 | $7,079,000 | +114.6% | 148,000 | +64.4% | 0.16% | +105.1% |
Q3 2016 | $3,298,000 | -28.8% | 90,000 | -21.7% | 0.08% | -31.9% |
Q1 2016 | $4,630,000 | -25.6% | 114,939 | +14.4% | 0.12% | -30.1% |
Q4 2015 | $6,223,000 | – | 100,485 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |